Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 1,500 shares, a decrease of 76.9% from the May 15th total of 6,500 shares. Based on an average trading volume of 4,300 shares, the short-interest ratio is presently 0.3 days.

Santen Pharmaceutical Stock Down 1.0%

OTCMKTS SNPHY opened at $11.73 on Friday. The stock has a 50-day moving average of $10.43 and a 200 day moving average of $10.11. Santen Pharmaceutical has a twelve month low of $8.65 and a twelve month high of $13.00.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.